Navigation Links
ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Date:11/10/2010

perpetually amplifying the destructive inflammatory cascade.  C5aR also mediates smooth muscle contraction, increasing vascular permeability and altering blood flow.  If left untreated, ANCA-associated vasculitis may lead to renal and pulmonary failure and is often fatal.  Current therapies include toxic treatments such as cyclophosphamide and high dose corticosteroids.  Under an alliance between ChemoCentryx and GlaxoSmithKline's (GSK's) Center of Excellence for External Drug Discovery (ceedd), GSK has the right to exercise an option to license CCX168 after Phase II clinical trials.  

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial. Phase III clinical trials of Traficet-EN are expected to initiate in the fourth quarter 2010. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus and associated complications; CCX354, a CCR1 antagonist
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... TAMPA, Fla. , May 22, 2015 /PRNewswire-USNewswire/ ... Hospital,s Heart Institute recently traveled to ... Convergent procedure at the 2015 Heart Rhythm Society ... experts together to focus on the ideas, people ... Convergent is a hybrid, minimally invasive ...
(Date:5/22/2015)... NEW YORK and KING OF PRUSSIA, ... Hemophilia Foundation (NHF) has awarded CSL Behring ... longstanding and unwavering commitment to advancing science and improving the ... by Paul Perreault , CEO and Managing Director, CSL ... New York City on May 21. ...
(Date:5/22/2015)... 2015   InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" ... ("EPS"), today announced that its CGuard TM Embolic Prevention ... Prof. Piotr Musialek , at the EuroPCR ... . PARADIGM, an investigator-initiated P rospective ... roti D revascularization I n symptomatic and increased-risk ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... Sept. 7 Symmetry Medical Inc. (NYSE: ... the global orthopedic device industry and other medical markets, ... and Chief Financial Officer, is scheduled to present at ... at the Stifel Nicolaus 2010 Healthcare Conference in Boston, ...
... MORRISTOWN, N.J., Sept. 7 Watson Pharmaceuticals, Inc. (NYSE: ... Watson Laboratories, Inc., has received approval from the United ... New Drug Application (ANDA) for Zarah™ (drospirenone and ethinyl ... Bayer,s Yasmin ® . Watson has begun shipping the ...
Cached Medicine Technology:Symmetry Medical to Present at Two Upcoming Conferences 2Watson's Generic Yasmin® Receives FDA Approval 2
(Date:5/22/2015)... Hands On HealthCare Massage Therapy and Wellness ... Annual One Day Sale on Massage and Facial Gift ... drastically reduced certificates one day a year. This sale ensures ... what used to be the slowest time of the year, ... well. This once a year occurrence has become a Commack ...
(Date:5/22/2015)... Carnegie Science Center and ... new partnership to develop BodyTech, a dynamic, three-pronged health ... includes a new exhibit at the Science Center called ... a new traveling science show, Anatomy Adventure, which will ... , Designed to explore a wide range of topics ...
(Date:5/22/2015)... 2015 According to a new Aegis Living ... equally as likely to worry about what will happen to ... 77% Boomers, 69% Silent Generation), which may help explain why ... of aging, particularly Millennials (47%), Gen X’ers (51%), and Boomers ... April, 2015 among more than 2,000 U.S. adults ages 18+. ...
(Date:5/22/2015)... ZH Healthcare (ZH), ... today that Bill Lane, joins ZH’s Advisory Board. ... BlueEHS,a first of its kind, Freemium SaaS, Electronic ... Health Records (EHR) with an integrated practice management ... patient portal, and more. Combined with its Revenue ...
(Date:5/22/2015)... 22, 2015 Gateway Building Concepts is ... The services the company specialize in include decks, additions, ... pool houses and much more. , The redesigned ... owner of the company. It includes two geometrical lines ... was thought out to be used with many things ...
Breaking Medicine News(10 mins):Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2
... leading all-women,s event series to ... promote a healthy lifestyle, NEW YORK, ... multi,year title sponsorship of Iron Girl. With 10 events nationwide, ranging,from ... to lead a healthy and active lifestyle., To illustrate the ...
... signed parental consent and health,history forms, Give Kids A ... population they will see on February 1 - primarily,coming ... and such. PLEASE DO NOT INDICATE TO THE PUBLIC ... Ohio, Jan. 24 In conjunction with,the Ohio Dental ...
... marrow, and known as MAPCs, have proved to be ... also in muscle tissue when treating peripheric vascular disease. ... models by two research groups, one by the University ... Medical Research (CIMA), also of the University of Navarra, ...
... (NIH) will invest more than $190 million over the next ... known as epigenomics. , "Disease is about more than genetics. ... they work in both health and disease," said NIH Director ... knowledge of the human genome and help us better understand ...
... primarily in the life sciences, protocols provide ... to recreate experiments in their own laboratory. ... and implementation of experiments that include the ... and troubleshooting standards for the experiment. ...
... understanding autistic disorders, incorporating both psychological and biological ... up earlier, research from UNSW has found. , ... and New Zealand Journal of Psychiatry, integrates psychological ... relates to autistic and Aspergers disorders, which are ...
Cached Medicine News:Health News:Aflac to Sponsor Iron Girl 2Health News:Aflac to Sponsor Iron Girl 3Health News:Ohio Dental Volunteers to Give Over $1.1M in Free Care and Improve Oral Health of 18,000 Children in Need Through 6th Annual Give Kids A Smile! Day Ohio 2Health News:Ohio Dental Volunteers to Give Over $1.1M in Free Care and Improve Oral Health of 18,000 Children in Need Through 6th Annual Give Kids A Smile! Day Ohio 3Health News:Adult stem cell application effective in treatment of peripheric vascular disease 2Health News:Adult stem cell application effective in treatment of peripheric vascular disease 3Health News:NIH announces new initiative in epigenomics 2Health News:NIH announces new initiative in epigenomics 3Health News:Springer launches Springer Protocols 2
... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
Medicine Products: